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Tamoxifen (Tam) is effective for the treatment and prevention of breast cancer. However, it has toxic drawbacks and has limited-
duration utility because, over time, human tumours become refractory to Tam. Recently, a new nontoxic peptide, a-fetoprotein-
derived peptide (AFPep) has been proposed for the treatment and prevention of breast cancer. The purpose of this paper is to
determine whether combining AFPep with Tam would increase efficacy and reduce toxicity in experimental models of breast cancer.
Low doses of AFPep and Tam were more effective in combination than either agent alone against breast cancer growth in cell
culture, in tumour-xenografted mice, and in carcinogen-exposed rats. a-Fetoprotein-derived peptide interfered with Tam-induced
uterine hyperplasia in immature mice, and showed no toxic effects. Unlike Tam, AFPep did not inhibit binding of oestradiol (E2)t o
oestrogen receptor (ER). Thus, these two agents utilise different mechanisms to interfere with ER functionality, yet work
cooperatively to reduce breast cancer growth and alleviate Tam’s troubling toxicity of uterine hyperplasia and appear to be a rational
combination for the treatment of ER-positive breast cancer.
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A peptide (a-fetoprotein-derived peptide (AFPep), sequence
cyclo(EKTOVNOGN), where O is hydroxyproline) derived from
the active site of a-fetoprotein (AFP) has been under investigation
as a potential agent for prevention or therapy of oestrogen receptor-
positive (ERþ) breast cancer (Mesfin et al, 2000, 2001; Bennett
et al, 2002, 2006; DeFreest et al, 2004). After identifying the active
site of AFP as an eight-amino acid peptide (Mesfin et al, 2000),
Mesfin went on to develop a more stable, cyclised peptide with
substantial potential as a pharmaceutical agent (Mesfin et al, 2001).
a-Fetoprotein-derived peptide has been shown to inhibit the growth
of human breast cancer xenografts in mice (Mesfin et al, 2001), and
prevent the development of carcinogen-induced mammary cancers
in rats (Parikh et al, 2005). It was also shown to inhibit the growth
of breast cancer that had become resistant to the cytostatic effects
of tamoxifen (Tam; Bennett et al, 2002). a-Fetoprotein-derived
peptide is active after oral administration (Bennett et al, 2002), and
has not exhibited toxicity in any study to date.
Tamoxifen has been the most widely used and effective drug for
the treatment of ERþ breast cancer for many years (Jordan,
1999a). It has been shown to inhibit breast cancer growth
(Lippman and Bolan, 1975), inhibit breast cancer recurrences
(Early Breast Cancer Trialists’ Collaborative Group, 1992), and
decrease the risk of primary breast cancers in high-risk patients
(Fisher et al, 1998). However, as mentioned above, some ERþ
breast cancers acquire resistance to Tam, and some are actually
resistant to Tam before treatment (Jensen and DeSombre, 1996).
Moreover, although Tam is relatively well tolerated, it is not
without unwanted sequelae in some patients. These toxicities and
side effects are generally dose-dependent and include uterine
hyperplasia, which can progress to uterine cancer in a small
percentage of patients; thrombo-embolic episodes that can
progress to deep vein thrombosis, pulmonary embolism, and
stroke in a small percentage of patients; and nonlife-threatening
side effects such as hot flashes, fluid retention, and vaginal
discharge (Mosby, 2005). Reducing Tam-induced toxicity and
providing alternatives to Tam for Tam-resistant tumours would
advance the treatment of breast cancer. We have been investigating
AFPep for these purposes (Mesfin et al, 2000, 2001; Bennett et al,
2002, 2006; DeFreest et al, 2004; Parikh et al, 2005). However, as
part of this investigation, it seemed reasonable to evaluate AFPep
in combination with Tam in that it might add to the therapeutic
activity of Tam, and perhaps might even reduce the toxicity or side
effects of Tam. This report describes results of AFPep in
combination with Tam in models of breast cancer therapy,
prevention, and host toxicity.
MATERIALS AND METHODS
Materials
Carcinogen (N-methyl-N-nitrosourea, MNU) was obtained from
the National Cancer Institute carcinogen repository (MRI Inc.,
Kansas City, MO, USA) and was dissolved in sterile physiological
saline (1%, w/v), buffered to pH 5.0 with 3% acetic acid. Female
Sprague–Dawley rats were obtained from Taconic Farms (Ger-
mantown, NY, USA) at 34 days of age and were placed immediately
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son a controlled diet (Agway Pro-Lab 2000; Agway Corporation,
Syracuse, NY, USA), allowed free access to food and water, and
maintained on a 12-h light–dark cycle at a constant temperature
(221C) for the duration of the study. Severe combined immune-
deficient (SCID) mice and Swiss Webster mice were obtained from
Taconic Farms and were maintained in individually ventilated
cages. Cages, bedding, food, and water for mice were autoclaved.
Mice were handled using sterile technique in a laminar flow
biosafety cabinet. All animal protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) at Albany
Medical College who are guided by the United States Public Health
Service regulations on the humane care and use of laboratory
animals, and these guidelines meet the standards required by the
UKCCCR (Workman et al, 1998).
Peptide synthesis
The AFP-derived peptide, cyclo(EKTOVNOGN), where O is
hydroxyproline, was generated using FMOC solid-phase peptide
synthesis employing the head-to-tail cyclisation method (Kates
et al, 1993). After synthesis, the resin was washed with propanol
and partially dried, and peptides were cleaved from the solid
support and deprotected simultaneously with 10ml of trifluoro-
acetic acid/thioanisole/anisole/ethanedithiol (90:5:2:3) per 0.5g
of resin for 5h. Peptide was recovered from the liquid phase after
repeated extraction, first with ether and then with ethyl acetate/
ether (1.5:1). The peptide was dissolved in water, purified by
reverse-phase HPLC, and then lyophilised. Biologically active
AFPep can also be purchased from PolyPeptide Laboratories
(Torrance, CA, USA) after synthesis by the tBOC method, or from
Advanced ChemTech (Louisville, KY, USA) after synthesis by the
FMOC method.
Cell culture assay
The MCF-7 cells were maintained in monolayer culture in
Dulbecco’s modification of Eagle’s medium (DMEM) supplemen-
ted with 5% fetal bovine serum, glutamine (2mM), nonessential
amino acids (1%), and bovine insulin (1mgml
 1). The T47D
human breast cancer cells were maintained in monolayer culture
in RPMI-1640 medium supplemented with 10% fetal bovine serum,
100IUml
 1 penicillin, 100mgml
 1 streptomycin, 0.25mgml
 1
amphotericin B, and 8mgml
 1 bovine insulin in T-75 flasks with
2–3 medium changes per week. Cells were maintained at 371Ci n
an atmosphere of 5% CO2, 95% air. To evaluate the oestrogen-
stimulated growth of these cells, they were released from
monolayer using 0.25% trypsin/0.53mM EDTA and suspended in
oestrogen-free medium comprised of DMEM (high glucose, phenol
red-free), supplemented with 10% charcoal-stripped bovine calf
serum, 2mM glutamine, 100IUml
 1 penicillin, and 100mgml
 1
streptomycin. One millilitre containing 1.2 10
5 cells was seeded
into each well of a 24-well plate coated with collagen IV (BD
Biosciences, Bedford, MA, USA). Beginning from 1 day after
seeding, cells were treated daily for 7 days with AFPep (10
 6 M),
Tam (10
 8 M), or the combination of AFPep plus Tam in the
presence or absence of E2(10
 9 M). In these groups exposed to E2,
E2 at 10
 9 M was added 1h after each addition of AFPep and Tam.
Control wells received the vehicle. Medium was changed every
other day before treatment. One day after the last treatment, cells
were trypsinised and resuspended in oestrogen-free medium, and
counted using a haemacytometer following dilution with trypan
blue. Viable cell number is reported.
Binding to oestrogen receptor
Rabbit uteri (Pel-Freez Biological, Rogers, AR, USA) were used as a
source of ER. Uteri were pulverised in a stainless-steel impact
mortar under liquid nitrogen and homogenised (20% w/v) in
buffer (10mM Tris, pH 7.4, 1.5mM EDTA, 10% glycerol, 10mM
monothioglycerol, and 10mM sodium molybdate) on ice. Cen-
trifugation (50000g) for 1h yielded cytosol, which was adjusted
with buffer to 2.5mg proteinml
 1. All incubations were carried out
in triplicate, each containing 100ml of cytosol, 20mlo f1 0 n M
6,7-[
3H]oestradiol (6,7-[
3H]E2), and 80ml of antagonist. After
incubation overnight at 41C, tubes received 300ml of dextran-
coated charcoal suspension; tubes were agitated for 15min, and
then centrifuged (1000g) for 15min. Supernatants were decanted
into counting vials, scintillation fluid was added, and protein-
bound tritium was determined (Mesfin et al, 2001).
Xenograft assay
Ten million MCF-7 human breast cancer cells were harvested from
culture, centrifuged into a pellet, solidified into a fibrin clot, and
implanted under the kidney capsule of SCID mice as described
previously (Bennett et al, 1985, 2002, 2006; Mesfin et al, 2001;
Parikh et al, 2005). Oestrogen supplementation was accomplished
by s.c. implantation of a 5mm silastic tubing capsule containing
solid E2 inserted on the day of tumour implantation. One
milligram of Tam was dissolved in 1ml 95% ethanol and then
diluted to 5 and 0.25mgml
 1 in saline; 0.2ml of these concentra-
tions was administered to mice. a-Fetoprotein-derived peptide was
dissolved directly in saline to its appropriate concentrations. Tam
was administered p.o. by gavage and AFPep was administered i.p.
once a day beginning from 1 day after tumour implantation. The
tumour-bearing kidney was exposed during survival laparotomy at
14 and 28 days after implantation and tumour size was measured
using a dissecting microscope equipped with an ocular micro-
meter, noting the long (D) and short (d) diameters of the tumour.
Five replicate mice were included in each treatment group. Mean
tumour volume (0.52d
2D) was calculated for each group, and used
for display of growth curves. Significance of differences between
groups was tested using the one-sided Wilcoxon rank sum test.
Prevention assay
The prevention study utilised methodologies previously described
(Grubbs et al, 1985; Parikh et al, 2005) to test the ability of AFPep,
Tam, or the combination of AFPep and Tam to prevent MNU-
induced breast cancers in rats. There were 30 rats in each
experimental group to assure a 95% probability of detecting a
difference between groups (ratios) of 40%, which was the
difference seen for pregnancy (Grubbs et al, 1983, 1985, 1986;
Swanson et al, 1997). Power analysis was performed by SOLO
software, BMDR Statistical Software Inc. (Los Angeles, CA, USA).
Female rats were housed three per cage in a room maintained at
22711C, and artificially lighted for 12h per day. At 50 days of age,
rats received a single injection of MNU (50mgkg
 1 body weight)
or vehicle in the jugular vein. N-methyl-N-nitrosourea was
administered to animals in the various treatment groups according
to a predetermined randomisation chart, so as to ensure uniform
distribution of the carcinogen across the groups. Beginning 10
days after MNU exposure, treatment with AFPep by s.c. injection,
or Tam by oral gavage, occurred once daily. These routes were
selected based on prior experience with these drugs in animals
(Bennett et al, 2002) and potential routes for these drugs in
women. To cause minimal stress to the animals, the route control
manipulation (i.e., vehicle injection in Tam animals and vehicle
gavage in AFPep animals) was not included. The peptide was
diluted in saline and 0.2ml was administered s.c. for 20 days, while
Tam was dissolved in corn oil and was administered by oral gavage
(0.2ml) for the same time period. A control group of animals
received daily 0.2ml s.c. injections of saline for the same time
period as AFPep administration and experienced the maximal
number of tumours. Starting 30 days after MNU treatment, all rats
were palpated weekly for detection of mammary tumours, noting
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snumber, location, and size. Tumour burden was determined
noninvasively using calipers to measure the long (D) and short (d)
diameter of each tumour. Assuming that tumours were ellipsoid
shaped, tumour volume was estimated as (0.52d
2D). Cage activity
of all animals was monitored daily for gross signs of toxicity. At
necropsy, body weight and organ weights were assessed as
indicators of toxicity.
Toxicity
To evaluate the effect of AFPep and Tam on uterine hyperplasia,
the immature mouse uterine growth assay was utilised (Mesfin
et al, 2001; Bennett et al, 2002; Parikh et al, 2005). Briefly, various
doses of AFPep and/or Tam were injected i.p. into 2-week old
female Swiss pups. Control mice received the vehicle. Twenty-two
hours later, uteri were harvested, trimmed free of connective
tissue, and weighed. Uterine weights were normalised to donor
mouse body weight. There were five replicate mice per group.
In the therapy model (human tumour xenografts growing in
mice) and in the prevention model (MNU-induced mammary
cancers in rats), the toxicity of AFPep, Tam, and AFP plus Tam
was evaluated by monitoring animal body weights, fur textures and
cage activity, and weights of specified organs at necropsy.
RESULTS
As shown in Figure 1A, either Tam or AFPep when used alone
inhibited the E2-stimulated growth of T47D human breast cancer
cells in culture. The combination of Tam plus AFPep demonstrated
cooperative growth inhibition as exemplified in Figure 1B in which
IC40 values of Tam plus AFPep produced an 80% inhibition of E2-
stimulated breast cancer growth. This is especially important when
one considers that the IC40 of Tam in these experiments was
approximately 100-fold lower than the IC80 of Tam, suggesting that
combination of Tam with AFPep would permit using a lower dose
of Tam without overall loss of antitumour activity. Additional
results described in subsequent figures support this important
concept. In data not shown, it was apparent that, at concentrations
ranging from 10
 8 to 10
 5 M, neither Tam nor AFPep inhibited the
basal (no E2) growth of T47D cells, suggesting that their action was
directed mainly to the E2 stimulation of these cells and was not a
nonspecific toxic effect. Also, a control peptide of scrambled
sequence did not inhibit the E2-stimulated or basal growth of these
cells (Bennett et al, 2006)
Although T47D cells were quite responsive to E2 in cell culture,
these cells were less reliable when grown as a xenograft in
immune-deficient mice, having a take rate (i.e., successful growth)
of o60% when implanted in 20 of these mice. In contrast, we have
found the MCF-7 human breast cancer cell line to have a tumour
take rate of 100% in immune-deficient mice and to be completely
dependent on E2 for growth in these mice. Hence, MCF-7
xenografts were used as a model of E2-dependent human breast
cancer being treated with AFPep and Tam in vivo. Again, several
doses of these drugs were evaluated in preliminary studies in this
model to find optimal and suboptimal doses, which were then
studied alone and in combination in the studies described herein.
As shown in Figure 2A, AFPep at a dose of 10mgmouse
 1day
 1 or
Tam at a dose of 1mgmouse
 1day
 1, completely prevented the
growth of MCF-7 tumour xenografts over a 30-day period. When
doses of AFPep or Tam were lowered to 0.1 and 0.05mg per mouse
per day, respectively, tumour growth occurred, although it was less
than tumour growth in nontreated mice (Figure 2B). Interestingly,
when AFPep and Tam were combined at these suboptimal doses,
MCF-7 tumour growth was completely prevented (Figure 2B),
again indicating that the maximal effect of Tam can be achieved at
a much lower dose of Tam, if it is combined with AFPep. The
validation of previous studies (Jacobson et al, 1990; Bennett et al,
1998, 2002; Mesfin et al, 2001; Parikh et al, 2005), which have
shown that MCF-7 tumours do not grow without E2 supplementa-
tion is not shown in Figure 2.
As a model for preventing the development of breast cancer, we
utilised the well-characterised system of carcinogen (MNU)-
induced mammary cancer in Sprague–Dawley rats (Grubbs et al,
1983, 1985, 1986; Swanson et al, 1997). When carcinogen-exposed
rats were treated with Tam at doses of 6.25mganimal
 1day
 1 or
higher, or AFPep at 270mganimal
 1day
 1, there was significant
inhibition of tumour formation, as shown in Table 1. These results
are similar to those of Moon et al (1992, 1994) using Tam and to
Parikh et al (2005) using AFPep. At a suboptimal dose of Tam or of
AFPep, inhibition of tumour formation was not significantly
diminished compared to controls (Table 1, Figure 3). When these
two drugs were used in combination at suboptimal doses, their
combined chemopreventive contribution resulted in a decrease in
tumour incidence (Figure 3, Table 1), which was significantly
below that seen in control (P¼0.04, Fisher’s exact). Doses of
AFPep (100mganimal
 1day
 1;) or of Tam (0.05mganimal
 1day
 1)
given to the rats were held constant during the 20-day treatment
interval. During this interval, all animals in all groups gained
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Figure 1 Inhibition of E2-stimulated growth of T47D human breast
cancer cells by AFPep and Tam. T47D (1 10
5) cells were seeded into
wells of collagen-coated plates in oestrogen-free medium. Medium was
changed daily. Twenty-four hours after seeding, AFPep and/or Tam were
added. One hour later E2 (10
 9 M) was added. Cells were treated daily for
7 days after which cells were harvested and counted in a hemacytometer.
Mean viable cell number of six replicate wells 7s.e. was determined. (A)
Concentration–response curve of each agent alone. Inhibition (%) of E2-
stimulated growth is reported. (’) Tam; (m) AFPep. (B) Effect of AFPep
and/or Tam on T47D cell proliferation. Mean viable cell number is
reported. E2,1 0
 9 M; AFPep, 10
 6 M; Tam, 10
 8 M (NT, no treatment).
*Po0.05 vs E2 alone, Dunnett’s test. **Po0.05 vs Tam alone, Scheffe’s
test.
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sweight from 165 to 190g, indicating that treatments did not affect
body weight. Table 1 shows that latency increased significantly,
multiplicity decreased, and tumour burden (volume) decreased
significantly following combination treatment with the lower doses
of AFPep in combination with Tam.
In all previous work with high doses of AFPep, no evidence of
toxicity or side effects has been detected (Mesfin et al, 2001;
Bennett et al, 2002, 2006; Parikh et al, 2005). In this study in which
AFPep or combination of AFPep and Tam were administered to
rats at therapeutic doses for 2–3 weeks, there was no effect on
body weight, fur texture, or cage activity during the lifespan of the
animals, or on organ weights obtained at necropsy (Table 1). At
these low doses, Tam had no effect on uterine growth, whether or
not AFPep was present.
A side effect of Tam is the induction of uterine hyperplasia in
approximately 30% of the patients taking this drug, and this
progresses to uterine cancer in roughly 0.2% of users (Fisher et al,
1994; Assikis and Jordan, 1995). As shown in Figure 4, Tam
stimulates the growth of immature mouse uterus. a-Fetoprotein-
derived peptide does not stimulate uterine growth. Moreover,
AFPep significantly inhibits the Tam-induced growth of the
immature mouse uterus. Therefore, in women, adding AFPep to
Tam would be expected to diminish the uterine growth side effect
of Tam.
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Figure 2 Inhibition of E2-stimulated growth of MCF-7 human breast
cancer xenografts by AFPep and Tam. Pieces of MCF-7 tumour were
implanted under the kidney capsule of SCID mice. Oestradiol was provided
via an E2-containing silastic tubing subcutaneous implant. Vehicle (K),
AFPep (m), Tam (’), or AFPepþTam (E) were injected once daily at
the doses indicated below beginning from 1 day after tumour implantation.
(A) Effective single-agent dose (10mg AFPep and 1mg Tam). (B)
Suboptimal single-agent dose (0.1mg AFPep and 0.05mg Tam). Mean
tumour volume of five replicate mice 7s.e. is reported. *Po 0.05 vs
vehicle; wPo0.05 vs Tam alone, Wilcoxon rank-sum test.
Table 1 Effect of AFPep and Tam on prevention of breast cancer in MNU-exposed rats
Treatment
Dose (lg/rat/
day)
Incidence,
a %
(P-value
b)
Multiplicity
c
(tumours/
rat)
Latency
d
(days)
Volume
e
(cm
3)
Body weight
(g)
Uterine
weight (g)
Heart weight
(g)
None (control) — 78 2.1 80731 69.0 283730 0.5470.15 1.1070.14
AFPep 270 40 (0.02) 0.5 88716 34.5* 280729 0.6270.17 1.0970.13
AFPep 100 63 (0.16) 1.1 97733 39.1* 285724 0.5270.15 1.1270.14
Tam 6.25 26 (0.001) 0.5 85715 70.2 273728 NA NA
Tam 0.05 73 (0.21) 1.3 95736 62.4 282731 0.4970.17 1.1270.13
AFPep+Tam 100+0.05 52 (0.04) 0.9 110733 32.6* 282729 0.5170.12 1.0970.15
AFPep¼a-fetoprotein-derived peptide; MNU¼N-methyl-N-nitrosourea; NA¼not applicable; Tam¼tamoxifen. *Po0.05 vs control.
aPercent of rats with one or more
tumours when killed (approximately 120 days after MNU exposure).
bP-value (calculated according to Fisher’s exact test) compared to control group.
cMultiplicity is defined as
total number of tumours/number of rats.
dMean number of tumour-free days7s.d.
eSum of the volumes of tumours in each group.
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Figure 3 Combination of suboptimal doses of AFPep and Tam prevents
breast cancer. Sprague–Dawley female rats (n¼30 ratsgroup
 1) received
MNU (50mgkg
 1) at the age of 50 days. Beginning after 10 days, rats were
treated once daily with vehicle (K), or a suboptimal dose of Tam (’,
50nganimal
 1, p.o.), or with a suboptimal dose of AFPep (m,
100mganimal
 1, s.c.) once daily for 20 days, or with both (E). Animals
were palpated weekly. The incidence of tumours is shown as a function of
time after carcinogen treatment.
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sMechanistically, AFPep is quite different from Tam. As shown in
Figure 5, AFPep did not inhibit the binding of [
3H]E2 to ER, while
Tam demonstrated the concentration-dependent inhibition of E2
binding expected from an ER antagonist. Also, in other studies, we
have shown that AFPep did not stimulate phosphorylation of ER at
serine 118 (Bennett et al, 2006), which is the phosphorylation site
stimulated by E2 (Kato et al, 1995). In contrast, it has been shown
that Tam stimulates phosphorylation of ER at serine 118, following
its binding to this receptor (Chen et al, 2002). Thus, Tam and
AFPep impact the ER in quite different ways, and yet work
cooperatively together to inhibit oestrogen-dependent breast
cancer growth.
DISCUSSION
Tamoxifen has been a very effective drug for the treatment of ERþ
breast cancer (Lippman and Bolan, 1975; Early Breast Cancer
Trialists’ Collaborative Group, 1992; Fisher et al, 1998; Jordan,
1999a). However, its effectiveness wanes with time, and after 2–5
years of treatment, most ERþ tumours become refractory to Tam
(Early Breast Cancer Trialists’ Collaborative Group, 1992; Jordan,
1999a). Also, there are some ERþ breast cancers that are
unresponsive to Tam at first presentation (Jensen and DeSombre,
1996), and there are others that, after chronic treatment with Tam,
actually become growth-stimulated by Tam (Canney et al, 1987;
Gottardis and Jordan, 1988; Howell et al, 1992). There are no good
tests to differentiate between these phenotypes, and it is possible
that seeds of each phenotype are present when breast cancer is first
diagnosed. One logical approach to this problem is to treat with
combinations of anti-endocrine agents using the prescribed
combination principles of each agent being active alone, having
different mechanisms of action and having non-cross-reacting host
toxicities. With this strategy, those phenotypes not held in check
by Tam would theoretically be arrested by the agent(s) combined
with Tam. Zaccheo et al (1991, 1993) have validated this principle
by showing that Tam plus examestane, an aromatase inhibitor, was
more effective than Tam alone in stopping breast cancer growth,
and now combinations of Tam plus aromatase inhibitors are
showing promise clinically (Abrial et al, 2006).
The data in the study reported herein support three independent
concepts: AFPep has antitumour activity on its own, it adds to the
antitumour activity of Tam through a mechanism distinct from
Tam, and it can reduce the toxicity of Tam by decreasing the
uterine hyperplasia of Tam and by allowing dose reduction of Tam
without loss of antitumour activity.
We have been studying AFPep as an inhibitor of oestrogen-
dependent growth (Mesfin et al, 2001; Bennett et al, 2002; Parikh
et al, 2005). a-Fetoprotein-derived peptide is not an ER antagonist,
nor an ER partial agonist, making its mechanism different from
Tam (Parikh et al, 2005; Bennett et al, 2006). Its function, at least
in part, is to inhibit the phosphorylation of ER that follows ligand
binding to ER. Phosphorylation has been shown to be necessary
for full functionality of ER (Kato et al, 1995). Furthermore, AFPep
does not share the toxicities of Tam. In fact, in this study and in
studies reported elsewhere (Bennett et al, 2002), AFPep interferes
with the uterine hyperplasia induced by Tam (i.e., reduces the
toxicity of Tam). The fact that AFPep inhibits Tam stimulation of
growth in the uterus suggests that AFPep may inhibit not only that
toxicity of Tam in humans but also those breast cancer phenotypes
that are actually stimulated by Tam, as well as those that are
indifferent to Tam. a-Fetoprotein-derived peptide clearly fits the
combination principles of being active when used alone, having a
different mechanism of action from Tam, and having non-cross-
reacting host toxicity with Tam. Hence, it was eminently logical to
postulate that AFPep would be beneficial in combination with
Tam, and the results of this study provide the data to support this
contention. Not only did AFPep plus Tam inhibit the growth of an
extant oestrogen-dependent human breast cancer better than Tam
alone, but also the combination was more effective than Tam alone
in preventing carcinogen-induced mammary cancers in rats. It
should not go unnoticed that in the effective combination, the dose
of Tam was substantially lower than that employed for Tam alone,
suggesting that such dose reduction may, in itself, alleviate Tam’s
toxicities (Jordan, 1999b). In addition, the data in Figure 4 suggest
that AFPep will further alleviate some of those toxicities as it
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
2.4
Vehicle AFPep Tam Tam+AFPep
N
o
r
m
a
l
i
s
e
d
 
u
t
e
r
i
n
e
 
w
e
i
g
h
t
 
(
m
g
g
–
1
)
 
  
  
Figure 4 Effect of AFPep and Tam on growth of immature mouse
uterus. Mice were injected i.p. with Tam (1mg), AFPep (10mg), or AFPep
plus Tam at the doses already indicated. In the case of the combination,
AFPep was given 1h before Tam. Twenty-two hours after treatment, uteri
were harvested, weighed, and normalised to mouse body weight. Mean
uterine weight of five replicate mice per group 7s.e. is reported. *Po0.05
vs Tam alone, Dunnett’s test.
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Figure 5 Effect of AFPep and Tam on binding of E2 to the ER. Rabbit
uterine cytosol was used as a source of ER. Test agents (80ml) at the final
concentrations indicated were incubated in triplicate with 100ml of cytosol,
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 1). The concentration of the
[
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sinhibits Tam-induced uterine hyperplasia. No toxicities from
AFPep have become evident. Since it is derived from a natural
human fetal protein (a-fetoprotein, AFP), and since its active dose
is below the fetal physiological level of AFP, it is possible that the
side effects associated with AFPep will, at most, be minimal. Thus,
it is highly unlikely that it will add to any of the toxicities of Tam,
and, as mentioned above, should alleviate some of those toxicities
while contributing to the antitumour activity of Tam. While the
study reported herein was ongoing, it was found that AFPep was
active by the oral route (Bennett et al, 2006). Hence, the discomfort
of chronic injections will not be an issue with use of AFPep as a
therapeutic or preventive agent.
Using a variety of models and species (human breast cancer cells
growing in culture, human breast cancer cells growing in a an
immune-deficient mouse model of therapy, or chemically induced
mammary carcinoma in a rat prevention model), the results of this
study have shown that AFPep works well in combination with Tam
for the treatment and prevention of experimental breast cancer. Its
mechanism is quite different from that of Tam, and its toxicity is
minimal. As such, AFPep warrants further development as a new
agent that could be used in combination with Tam, or perhaps
even used as a stand-alone agent, for the treatment or prevention
of breast cancer in humans.
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